SCHEMBL7977384

SCHEMBL7977384

Cc1ccc(C)n1-c1cccc(-c2ccc(OCc3ccccc3C3CCC3)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
NMT1 P30419 2/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
IGF1R P08069 3/20 0.34
HTR6 P50406 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
WDR5 P61964 1/20 0.33
ENPP3 O14638 1/20 0.33
ENPP1 P22413 1/20 0.33
CD274 Q9NZQ7 1/20 0.33
ALOX5 P09917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7975001 0.96 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3NMT1PPARD
SCHEMBL6586756 0.76 ALOX5AP (0.41) IGF1RRAB9AALOX5APFEN1ALOX5
SCHEMBL6583443 0.74 ALOX5AP (0.41) IGF1RRAB9AALOX5APFEN1ALOX5
SCHEMBL6581983 0.71 MEN1 (0.41) RAB9AALOX5
SCHEMBL2969912 0.69 RAB9A (0.54) MAPTKDM4ERAB9A
SCHEMBL6587036 0.68 TYR (0.37) KDM4EGAARAB9AALOX5APFEN1
SCHEMBL6703073 0.67 DRD2 (0.47)
SCHEMBL7975037 0.67 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3MAPTGAA
SCHEMBL6703720 0.67 HTR3A (0.41)
SCHEMBL7973873 0.67 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3HTR6RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... PFIZER INC. 2001-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010007873-A1 Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... NOS1, PTGS1, NOS2 SLC6A2 258/4885SLC6A4 1375/4885SLC6A3 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.